Topoisomerase I activity and sensitivity to camptothecin in breast cancer-derived cells: a comparative study

BACKGROUND: Camptothecin (CPT) and its derivatives are currently used as second- or third-line treatment for patients with endocrine-resistant breast cancer (BC). These drugs convert nuclear enzyme DNA topoisomerase I (TOP1) to a cell poison with the potential to damage DNA by increasing the half-li...

Descripción completa

Detalles Bibliográficos
Autores principales: Tesauro, Cinzia, Simonsen, Anne Katrine, Andersen, Marie Bech, Petersen, Kamilla Wandsoe, Kristoffersen, Emil Laust, Algreen, Line, Hansen, Noriko Yokoyama, Andersen, Anne Bech, Jakobsen, Ann Katrine, Stougaard, Magnus, Gromov, Pavel, Knudsen, Birgitta R., Gromova, Irina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884793/
https://www.ncbi.nlm.nih.gov/pubmed/31783818
http://dx.doi.org/10.1186/s12885-019-6371-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884793/
https://www.ncbi.nlm.nih.gov/pubmed/31783818
http://dx.doi.org/10.1186/s12885-019-6371-0

Ejemplares similares